Mitoxantrone
Authors:
- R. BuzzoniRBR. Buzzoni
- P. ValagussaPVP. Valagussa
- G. BonadonnaGBG. Bonadonna
- 1 April 1988
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 11 (2) , 100-103
Abstract
A phase II oriented study with mitoxantrone was undertaken in 31 patients with refractory non-Hodgkin's lymphomas (NHL); 30 patients had evaluable disease. The drug was administered through a 30-min intravenous infusion at the dose of 14 mg/m2 every 3 weeks. A minimum of two cycles were required to define treatment response. Twenty patients were previously treated with Adriamycin whose total dose was not exceeding 300 mg/m2. Complete response (CR) was documented in 9 patients, and partial response (PR), in 5 for a total response rate of 47% (14 of 30). Of 20 patients previously treated with Adriamycin, CR occurred in five and PR in two. The median time to progression was 3 months. Mitoxantrone was well tolerated, and no patient refused treatment. Mild leukopenia was evident in 10 patients and thrombocytopenia in 5 patients. In all cases, electrocardiograms (EKGs) was obtained before each treatment cycle. Systolic time intervals and left ventricular ejection fraction were repeated after 3 cycles and at the end of therapy. Laboratory tests failed to document any major cardiac abnormality. Mitoxantrone is an effective agent in refractory NHL and should be taken into consideration in the design of salvage regimens.Keywords
This publication has 5 references indexed in Scilit:
- Weekly Mitoxantrone Therapy of Hodgkinʼs Disease, Non-Hodgkinʼs Lymphoma, and Chronic Lymphocytic Leukemia A Southeastern Cancer Study Group TrialAmerican Journal of Clinical Oncology, 1987
- Mitoxantrone: A New Anticancer Drug with Significant Clinical ActivityAnnals of Internal Medicine, 1986
- Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, with nucleic acidsBiochemical Pharmacology, 1981
- COMBINATION OF DIHYDROXYANTHRAQUINONE AND RADIATION ON L1210 MURINE LEUKEMIA1981
- EXPERIMENTAL ANTI-TUMOR ACTIVITY OF AMINOANTHRAQUINONES1979